Limitations of homologous recombination status testing and poly (ADP-ribose) polymerase inhibitor treatment in the current management of ovarian cancer

Homologous recombination (HR) is a highly conserved DNA repair system, in which aberrations can lead to the accumulation of DNA damage and genomic scars known as homologous recombination deficiency (HRD). The identification of mutations in key genes (i.e., BRCA1, and BRCA2 (BRCA)) and the quantifica...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Qianying Zhao, Liping Bai, Yu Tan, Mingrong Qie
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2024-07-01
Edice:	Frontiers in Oncology
Témata:	homologous recombination (HR) PARP inhibitor (PARPi) ovarian cancer (OC) future prospect limitations
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1435029/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!